The pharmacokinetics, pharmacodynamics and safety of oral doses of ilaprazole 10, 20 and 40 mg and esomeprazole 40 mg in healthy subjects: a randomised, open‐label crossover study - Shin, J. S.; Lee, J. Y.; Cho, K. H.; Park, H. L.; Kukulka, M.; Wu, J.‐T.; Kim, D. Y.; Park, S.‐H. (Alimentary pharmacology & therapeutics, 2014)
Keywords: 2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage; 2-Pyridinylmethylsulfinylbenzimidazoles - adverse effects; 2-Pyridinylmethylsulfinylbenzimidazoles - blood; 2-Pyridinylmethylsulfinylbenzimidazoles - pharmacokinetics; Administration, Oral; Adult; Anti-Ulcer Agents - administration & dosage; Anti-Ulcer Agents - adverse effects; Anti-Ulcer Agents - blood; Anti-Ulcer Agents - pharmacokinetics; Biological and medical sciences; Blood. Blood coagulation. Reticuloendothelial system; Cross-Over Studies; Esomeprazole - administration & dosage; Esomeprazole - adverse effects; Esomeprazole - blood; Esomeprazole - pharmacokinetics; Female; Gastrins - blood; Healthy Volunteers; Humans; Hydrogen-Ion Concentration; Male; Medical sciences; Middle Aged; Pharmacology. Drug treatments; Proton Pump Inhibitors - administration & dosage; Proton Pump Inhibitors - adverse effects; Proton Pump Inhibitors - blood; Proton Pump Inhibitors - pharmacokinetics; Human; Pharmacokinetic pharmacodynamic relationship; Healthy subject; Enzyme; Toxicity; Oral administration; H; Enzyme inhibitor; Antiulcer agent; K; Crossover study; Proton pump inhibitor; Randomization; Benzimidazole derivatives; Antisecretory agent; Esomeprazole; exchanging ATPase; Hydrolases; Ilaprazole; Pharmacokinetics; Dose